Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention | The Journal of Headache and Pain | Full Text

Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention | The Journal of Headache and Pain | Full Text



The Journal of Headache and Pain

Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

• Russell NicholsEmail authorView ORCID ID profile,
• Vladimir Skljarevski,
• Grazia Dell’Agnello,
• Hans-Peter Hundemer and
• Sheena K. Aurora

The Journal of Headache and PainOfficial Journal of the "European Headache Federation" and of "Lifting The Burden - The Global Campaign against Headache"201920:22

https://doi.org/10.1186/s10194-019-0975-2

©  The Author(s). 2019

• Received: 11 February 2019
• Accepted: 20 February 2019
• Published: 1 March 2019

The Correction to this article has been published in The Journal of Headache and Pain 2019 20:58

To the Editor,

We were excited to see the online publication of the European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention [1]. These guidelines provide timely information for clinicians, payers, and ultimately patients in the preventive treatment of migraine and including all available and pertinent information is crucial.

While reviewing the guidelines, we noticed that EVOLVE-2, one of the galcanezumab phase 3 studies in episodic migraine, was completely omitted. Because of this, all data from this study were not considered and associated levels of certainty were downgraded throughout the publication. The guidelines reference that there was a study called EVOLVE-2, however; the reference associated with EVOLVE-2 by Skljarevski et al. [2] is a phase 2 dose finding study and the data points in Table 1 correspond to that study. Skljarevski was also the primary author for the EVOLVE-2 publication in 2018 [3] and we believe this may have led to the error. Both EVOLVE-1 and EVOLVE-2 should be accounted for in the guidelines.

EVOLVE-1 and EVOLVE-2 were identically designed phase 3 studies and 26% of the patients in EVOLVE-2 were from Europe. Because there were similar/consistent endpoint results between the two, we believe that multiple sections in the guidelines need to be updated. Of note, the “certainty of the evidence (GRADE)” levels in multiple tables appear to have been downgraded since only 1 phase 3 study in episodic migraine for galcanezumab was noted. We believe that all levels of evidence and associated data for galcanezumab in episodic migraine within the article should be reviewed and updated based on the inclusion of EVOLVE-2 as a phase 3 study.

We acknowledge and thank the consensus panel and all involved in the creation of the guidelines for their countless hours and hard work. However, with this error and omission, we believe that the guidelines need to be updated to ensure an accurate and fair representation of the data.

Declarations

Acknowledgements

Not Applicable.

Funding

Not Applicable.

Availability of data and materials

EVOLVE-2 publication is available online at https://journals.sagepub.com/doi/abs/10.1177/0333102418779543

Authors’ contributions

All authors (RN, VS, GD, HH, and SA) participated in the conception of the letter and were major contributors for the drafting of the manuscript. All authors read and approved the final letter.

Ethics approval and consent to participate

The study protocols were reviewed and approved by the appropriate institutional review board for each of the study sites. The studies were conducted according to Good Clinical Practice and the Declaration of Helsinki guidelines. Patients provided written informed consent before undergoing study procedures.

Consent for publication

Not applicable.

Competing interests

All Authors (RN, VS, GD, HH, and SK) are all employees of Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN, USA.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Sacco S, Bendtsen L, Ashina M et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. In: The journal of headache and pain. https://doi.org/10.1186/s10194-018-0955-yAccessed 18 Jan 2019View ArticleGoogle Scholar
2. Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A, Goadsby PJ, Dodick DW (2018) Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol 75:187–193View ArticleGoogle Scholar
3. Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE–2 phase 3 randomized controlled clinical trial. Cephalalgia. 38:1442–1454View ArticleGoogle Scholar

Copyright

© The Author(s). 2019